6-K
BRIGHT MINDS BIOSCIENCES INC. (DRUG)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2021
Commission File No. 000-56296
BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English)
19 Vestry Street, New York, NY 10013 (Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
Form 20-F [X] Form 40-F [ ]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1) [ ]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7) [ ]
SUBMITTED HEREWITH
| Exhibits | **** |
|---|---|
| 99.1 | News Release dated October 6, 2021 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
BRIGHT MINDS BIOSCIENCES INC.
/s/ Ryan Cheung__________________ Ryan Cheung Chief Financial Officer
Date: October 19, 2021
Bright Minds Biosciences Inc.: Exhibit 99.1 - Filed by newsfilecorp.com
Bright Minds Biosciences to Present at the LD Micro Main Event Small Cap Investment Conference
Vancouver, BC - October 6, 2021 - Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain, today announced that Ian McDonald, Chief Executive Officer of Bright Minds, will present at the LD Micro Main Event Small Cap Investment Conference as follows:
Date: Tuesday, October 12, 2021
Time: 12:30PM PT/3:30PM ET
Webcast: https://me21.mysequire.com/
Bright Minds' management team will also be conducting meetings with institutional investors throughout the conference. To schedule a meeting, please visit https://www.meetmax.com/sched/event_76871/conference home.html.
An archived replay of the presentation will be available on the Company's website immediately following the conference and will be available for 90 days at: https://brightmindsbio.com/investors/.
About Bright Minds
Bright Minds is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy and pain. Bright Minds has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The Company leverages its world-class scientific and drug development expertise to bring forward the next generation of safe and efficacious drugs. Bright Minds' drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
Investor Contact:
Lisa Wilson
E: lwilson@insitecony.com
In-Site Communications, Inc. T: +1-917-543-9932